AVRO - AVROバイオ (AVROBIO Inc.) AVROバイオ

 AVROのチャート


 AVROの企業情報

symbol AVRO
会社名 AVROBIO Inc (AVROバイオ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 AVROBIO Inc. is a clinical stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01 AVR-RD-02 AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.   AVROバイオは米国のバイオ医薬品企業。臨床段階で、主に希少疾患に対する遺伝子治療に焦点を当てた医薬品の開発・商業化に従事する。同社はリソソ―ム蓄積症に対する幹細胞遺伝子治療を開発し、一度の投与で効果を表す医薬品を手がける。パイプラインにはゴ―シェ病、ポンペ病、シスキシン症の治療薬を含む。本社所在地はマサチュ―セッツ州ケンブリッジ。   
本社所在地 One Kendall Square Building 300 Suite 201 Cambridge MA 02139 USA
代表者氏名 Bruce Booth ブルースブース
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 781-962-6030
設立年月日 42309
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 34人
url www.avrobio.com
nasdaq_url https://www.nasdaq.com/symbol/avro
adr_tso
EBITDA EBITDA(百万ドル) -31.03900
終値(lastsale) 25.6
時価総額(marketcap) 612783052.8
時価総額 時価総額(百万ドル) 578.31400
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 423.29900
当期純利益 当期純利益(百万ドル) -35.06700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Avrobio Inc revenues was not reported. Net loss applicable to common stockholders increased from $4.7M to $21M. Higher net loss reflects Research and developme increase from $3.3M to $12.9M (expense) General and administrative increase from $1.2M to $3.9M (expense) Gains/Losses on Trading Derivatives increase from $35K to $1.6M (expense).

 AVROのテクニカル分析


 AVROのニュース

   AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update  2021/03/18 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2020 and provided a business update. “It has been a highly productive period for AVROBIO, with strong new data updates across all our clinical programs, underscoring the transformative potential of our ex vivo lentiviral gene therapies. Most
   AVROBIO Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/03/15 17:51:00 Stock Market Daily
AVROBIO announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑04, an Investigational Gene Therapy for Cystinosis  2021/03/01 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-04, the company’s investigational gene therapy for the treatment of cystinosis. AVR-RD-04 consists of the patient’s own hematopoietic stem cells, genetically modified to express cystinosin, the protein that is deficient in pa
   AVROBIO to Present at Three Upcoming Investor Conferences in March  2021/02/25 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming virtual investor conferences. Cowen 41st Annual Health Care Conference Panel: Orphan CNS Date: Thursday, March 4, 2021 Time: 10:30 a.m. ET Barclays Global Healthcare Conference Date: Tuesday, March 9, 2021 Time: 8:35
   Gene therapy leaders may need M&A to solve their safety issues. Here are the 8 companies analysts are watching.  2021/02/24 18:02:15 Business Insider
Summary List Placement Reports of patients deaths, cancer cases, and other potential safety issues in the gene therapy field have made some investors skittish and could create a ripple effect across the multi-billion-dollar field . Gene therapies are a relatively new and complex type of treatment for genetic diseases. They work by inserting a normal, functioning gene into the bone marrow, the liver or another part of the body to take over for an abnormal gene. While hundreds of gene therapies are being developed, only four have been approved in the US. One of the more advanced candidates ran into trouble last week when two participants in a biotech's gene therapy trial for the blood disorder sickle cell disease developed forms of cancer . Cambridge, Massachusetts-based bluebird bio disclosed that one clinical trial participant was diagnosed with acute myeloid leukemia and another developed myelodysplastic syndrome, a type of cancer affecting bone marrow cells. Sickle cell patients are more likely to develop myelodysplastic syndrome, but there is a concern that bluebird's treatment played a role in these cases.
   AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑04, an Investigational Gene Therapy for Cystinosis  2021/03/01 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-04, the company’s investigational gene therapy for the treatment of cystinosis. AVR-RD-04 consists of the patient’s own hematopoietic stem cells, genetically modified to express cystinosin, the protein that is deficient in pa
   AVROBIO to Present at Three Upcoming Investor Conferences in March  2021/02/25 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming virtual investor conferences. Cowen 41st Annual Health Care Conference Panel: Orphan CNS Date: Thursday, March 4, 2021 Time: 10:30 a.m. ET Barclays Global Healthcare Conference Date: Tuesday, March 9, 2021 Time: 8:35
   Gene therapy leaders may need M&A to solve their safety issues. Here are the 8 companies analysts are watching.  2021/02/24 18:02:15 Business Insider
Summary List Placement Reports of patients deaths, cancer cases, and other potential safety issues in the gene therapy field have made some investors skittish and could create a ripple effect across the multi-billion-dollar field . Gene therapies are a relatively new and complex type of treatment for genetic diseases. They work by inserting a normal, functioning gene into the bone marrow, the liver or another part of the body to take over for an abnormal gene. While hundreds of gene therapies are being developed, only four have been approved in the US. One of the more advanced candidates ran into trouble last week when two participants in a biotech's gene therapy trial for the blood disorder sickle cell disease developed forms of cancer . Cambridge, Massachusetts-based bluebird bio disclosed that one clinical trial participant was diagnosed with acute myeloid leukemia and another developed myelodysplastic syndrome, a type of cancer affecting bone marrow cells. Sickle cell patients are more likely to develop myelodysplastic syndrome, but there is a concern that bluebird's treatment played a role in these cases.
   Why Moderna, Avrobio, And More Are Moving Today  2021/02/08 17:23:03 Benzinga
Moderna (NASDAQ: MRNA ) shares are trading higher amid South … Full story available on Benzinga.com
   AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial  2021/02/08 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced a 100% reduction, or complete clearance, of toxic substrate in the kidney biopsy of the first patient dosed with the plato® gene therapy platform in the ongoing Phase 2 FAB-GTi clinical trial of AVR-RD-01, an investigational ex vivo lentiviral gene therapy for Fabry disease. Kidney substrate reduction is
   Why Moderna, Avrobio, And More Are Moving Today  2021/02/08 17:23:03 Benzinga
Moderna (NASDAQ: MRNA ) shares are trading higher amid South … Full story available on Benzinga.com
   AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial  2021/02/08 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced a 100% reduction, or complete clearance, of toxic substrate in the kidney biopsy of the first patient dosed with the plato® gene therapy platform in the ongoing Phase 2 FAB-GTi clinical trial of AVR-RD-01, an investigational ex vivo lentiviral gene therapy for Fabry disease. Kidney substrate reduction is
   AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2021/02/05 21:05:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 10,250 shares of the company’s common stock to a new employee as an inducement award under the company’s 2019 Inducement Plan. In addition, the company granted a non-statutory stock option for the purchase of up to 130,000
   AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17th Annual WORLDSymposium™ 2021  2021/02/01 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will host a virtual investor event to discuss new data from AVROBIO’s clinical programs in Fabry disease, cystinosis and Gaucher disease type 1 presented at the virtual 17th annual WORLDSymposium™, a scientific meeting dedicated to lysosomal disorders, Feb. 8-12, 2021. The company also will host t
   AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit  2021/01/22 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Azadeh Golipour, VP of Manufacturing Operations at AVROBIO, will present virtually at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit at 11:30 a.m. ET on Friday, Jan. 29, 2021. About AVROBIO Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease t

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 AVROバイオ AVRO AVROBIO Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)